盐酸羟考酮缓释片用于治疗中重度癌痛12h调整剂量的临床研究

Clinical study of 12h adjusted dose of oxycodone hydrochloride sustained-release tablets in the treatment of moderate to severe cancer pain

目的:研究对中重度癌痛患者进行盐酸羟考酮缓释片12 h调整剂量治疗的临床效果。方法:择取2020年6月至2021年6月在怀集县人民医院住院治疗的80例中重度癌痛患者,以盐酸羟考酮缓释片剂量调整时间为依据将其分为研究组和对照组,每组40例患者。研究组12 h调整剂量,对照组24 h调整剂量,对比两组的疼痛评分及用药后24 h、48 h、72 h的疼痛缓解率,观察其中出现不良反应、入院治疗12 h内出现爆发痛患者的例数,评估治疗前后其睡眠质量。结果:1)疼痛评分:入院时,两组的疼痛评分相比,差异无统计学意义(P>0.05)。治疗后,两组的疼痛评分均显著下降,且研究组低于对照组,差异有统计学意义(P<0.05)。2)疼痛缓解率:研究组用药后24 h、48 h的疼痛缓解率高于对照组,差异有统计学意义(P<0.05)。两组用药后72 h的疼痛缓解率相比,差异无统计学意义(P>0.05)。3)不良反应:两组不良反应的发生率相比,差异无统计学意义(P>0.05)。4)爆发痛:入院治疗12 h内,研究组爆发痛的发生率低于对照组,差异有统计学意义(P<0.05)。5)睡眠质量:治疗前,两组的睡眠质量评分相比,差异无统计学意义(P>0.05)。治疗后,两组的睡眠质量评分均显著下降,且研究组低于对照组,差异有统计学意义(P<0.05)。结论:对于中重度癌痛患者来说,进行盐酸羟考酮缓释片12 h调整剂量治疗可在更短时间内控制其疼痛症状,对其睡眠质量也有改善作用,且安全性较高。

Objective:To study the clinical effect of 12 h adjusted dose of oxycodone hydrochloride sustained-release tablets in patients with moderate to severe cancer pain.Methods:A total of 80 patients with moderate to severe cancer pain who were hospitalized in Huaiji County People’s Hospital from June 2020 to June 2021 were selected and divided into study group and control group according to the dose adjustment time of oxycodone hydrochloride sustained release tablets,with 40 patients in each group.The dose was adjusted at 12 h in the study group and 24 h in the control group.The pain scores and pain relief rates at 24 h,48 h and 72 h after treatment were compared between the two groups.The number of patients with adverse reactions and outbreak pain within 12 h after admission was observed,and the sleep quality before and after treatment was evaluated.Results:1)Pain score:At admission,there was no signi ficant difference in pain score between the two groups(P>0.05).After treatment,the pain scores of the two groups were significantly decreased,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).2)Pain relief rate:The pain relief rate of the study group was higher than that of the control group at 24 h and 48 h after medication,and the difference was statistically significant(P<0.05).There was no significant difference in pain relief rate between the two groups at 72 h after treatment(P>0.05).3)Adverse reactions:There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).4)Burst pain:Within 12 hours after admission,the incidence of burst pain in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).5)Sleep quality:Before treatment,there was no significant difference in sleep quality scores between the two groups(P>0.05).After treatment,the sleep quality scores of the two groups were significantly decreased,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion:For patients with moderate to severe cancer pain,12 h adjusted dose of oxycodone hydrochloride sustained-release tablets can control their pain symptoms in a shorter time,improve their sleep quality,and has high safety.